EGFR and non-small cell lung carcinoma: Although in-vitro studies suggest that non-small cell lung cancer (NSCLC) cell lines with EGFR mutations have increased sensitivity to radiation compared to EGFR wild-type cell lines [9], it is unclear if patients harbouring these mutations have improved clinical outcomes when treated with definitive TRT compared with patients with EGFR wild-type status.